Bevacizumab in combination with taxanes for the first-line treatment of metastatic breast cancer.

Arlene Chan; D. W. Miles; Xavier Pivot

doi:10.1093/annonc/mdq122

Journal articles

Bevacizumab in combination with taxanes for the first-line treatment of metastatic breast cancer.

Arlene Chan ^{1, 2} D. W. Miles ^{1, 3} Xavier Pivot ^{1, 4}

1 Service d'Oncologie Médicale [CHRU Besançon]

2 Medical Oncology

3 Medical Oncology

4 RIGHT - Interactions hôte-greffon-tumeur, ingénierie cellulaire et génique - UFC (UMR INSERM 1098)

Abstract : Bevacizumab-taxane combinations provide an alternative to chemotherapy doublet regimens in first-line mBC, with equivalent efficacy and potentially lower toxicity. Ongoing trials are investigating the efficacy and safety of bevacizumab in various stages of breast cancer and in breast cancer with a range of hormonal or receptor characteristics.

Document type :

Journal articles

Domain :

Life Sciences [q-bio] / Immunology

Complete list of metadata

https://www.hal.inserm.fr/inserm-00484825
Contributor : Philippe Saas Connect in order to contact the contributor
Submitted on : Wednesday, May 19, 2010 - 11:54:14 AM
Last modification on : Friday, January 14, 2022 - 3:08:20 AM

Bevacizumab in combination with taxanes for the first-line treatment of metastatic breast cancer.

Links full text

Identifiers

Collections

Citation

Export

Metrics

45

Bevacizumab in combination with taxanes for the first-line treatment of metastatic breast cancer.

Links full text

Identifiers

Collections

Citation

Export

Share

Metrics

45